Table 4:
Outcomes following convergent ablation
| Outcome | |
|---|---|
| Freedom from AF recurrence on/off AADs at 1 year, % (n) | 81.3 (52) |
| Freedom from AF recurrence and off AADs at 1 year, % (n) | 68.8 (44) |
| Freedom from AF/AT/AFL at 1 year, % (n) | 69.2 (45) |
| mEHRA class 1 (asymptomatic) at 1 year, % (n) | 75.0 (48) |
| Overall freedom from AF recurrence, % (n) | 61.5 (40) |
| Overall freedom from AF/AT/AFL, % (n) | 44.6 (29) |
| Incidence of AT/AFL post-blanking period, % (n) | 30.8 (20) |
| DCCV required in blanking period, % (n) | 22.4 (15) |
| DCCV required post-blanking period, % (n) | 30.8 (20) |
| Repeat AF ablation, % (n) | 16.9 (11) |
| Repeat ablation for AT/AFL only, % (n) | 12.3 (8) |
AADs: anti-arrhythmic drugs; AF: atrial fibrillation; AFL: atrial flutter; AT: atrial tachycardia; DCCV: direct current cardioversion; mEHRA: modified EHRA.